Literature DB >> 27613176

Clinical recovery and health-related quality of life in ischaemic stroke survivors receiving thrombolytic treatment: a 1-year follow-up study.

Barbara Grabowska-Fudala1, Krystyna Jaracz2, Krystyna Górna2, Jan Jaracz3, Radosław Kaźmierski4.   

Abstract

The aims of this study were to examine prospectively the course of neurological and functional recovery and health related quality of life (HRQoL) in ischaemic stroke patients after intravenous thrombolysis, to assess the 1-year outcome and to determine the early predictors. A group of 53 consecutive patients were assessed at admission to the acute stroke unit (T0), before their discharge (T1), and at 3 (T2) and 12 (T3) months after hospital discharge. The National Institutes of Health Stroke Scale (NIHSS), the Barthel Index (BI) and the Stroke Specific Quality of Life Scale (SSQoL) were used to evaluate stroke severity, functional disability and health related quality of life (HRQoL). A good outcome was defined as simultaneous improvement in all three scales. At T0, 83 % of the patients had severe or moderate neurological impairment. Additionally, 77 % demonstrated very severe or severe disability when assessed by the BI. 74 and 79 % of the patients reported an acceptable HRQoL at 3 and 12 months following discharge, respectively. Neurological and functional status improved significantly over time with most changes occurring during hospitalization and the subsequent 3 months. At T3, 75.5 % of the patients had the good outcome which had been independently predicted by the level of stroke related disability at T0. A majority of the stroke survivors treated with thrombolysis achieved a good outcome. The measurement of stroke specific HRQoL, as a tool for gathering information from the patient, should be incorporated in the assessment of post-stroke recovery and outcome.

Entities:  

Keywords:  Clinical status; Outcome; Quality of life; Stroke; Thrombolytic therapy

Mesh:

Year:  2017        PMID: 27613176     DOI: 10.1007/s11239-016-1419-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  34 in total

1.  Targeting the ischemic penumbra.

Authors:  Pedro Ramos-Cabrer; Francisco Campos; Tomás Sobrino; José Castillo
Journal:  Stroke       Date:  2010-12-16       Impact factor: 7.914

2.  Impact of time on improvement of outcome after stroke.

Authors:  Gert Kwakkel; Boudewijn Kollen; Jos Twisk
Journal:  Stroke       Date:  2006-08-24       Impact factor: 7.914

3.  Development of a stroke-specific quality of life scale.

Authors:  L S Williams; M Weinberger; L E Harris; D O Clark; J Biller
Journal:  Stroke       Date:  1999-07       Impact factor: 7.914

4.  Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke.

Authors:  Leonard L L Yeo; Prakash Paliwal; Hock L Teoh; Raymond C Seet; Bernard P L Chan; Benjamin Wakerley; Shen Liang; Rahul Rathakrishnan; Vincent F Chong; Eric Y S Ting; Vijay K Sharma
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-08-15       Impact factor: 2.136

5.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.

Authors:  Martin J O'Donnell; Denis Xavier; Lisheng Liu; Hongye Zhang; Siu Lim Chin; Purnima Rao-Melacini; Sumathy Rangarajan; Shofiqul Islam; Prem Pais; Matthew J McQueen; Charles Mondo; Albertino Damasceno; Patricio Lopez-Jaramillo; Graeme J Hankey; Antonio L Dans; Khalid Yusoff; Thomas Truelsen; Hans-Christoph Diener; Ralph L Sacco; Danuta Ryglewicz; Anna Czlonkowska; Christian Weimar; Xingyu Wang; Salim Yusuf
Journal:  Lancet       Date:  2010-06-17       Impact factor: 79.321

6.  Depressive symptoms and quality of life after thrombolysis in stroke: the TEMPiS study.

Authors:  Susanne Schwab-Malek; Bijan Vatankhah; Ulrich Bogdahn; Markus Horn; Heinrich J Audebert
Journal:  J Neurol       Date:  2010-06-18       Impact factor: 4.849

7.  Responsiveness and sensitivity of the Stroke Specific Quality of Life Scale Danish version.

Authors:  Ingrid Muus; Doris Christensen; Max Petzold; Ingegerd Harder; Søren Paaske Johnsen; Marit Kirkevold; Karin C Ringsberg
Journal:  Disabil Rehabil       Date:  2011-04-27       Impact factor: 3.033

8.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

Review 9.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.

Authors:  Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory del Zoppo; Peter Sandercock; Richard L Lindley; Geoff Cohen
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

10.  Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.

Authors: 
Journal:  Lancet Neurol       Date:  2013-06-21       Impact factor: 44.182

View more
  3 in total

1.  Depressive symptoms in stroke patients treated and non-treated with intravenous thrombolytic therapy: a 1-year follow-up study.

Authors:  Barbara Grabowska-Fudala; Krystyna Jaracz; Krystyna Górna; Izabela Miechowicz; Izabela Wojtasz; Jan Jaracz; Radosław Kaźmierski
Journal:  J Neurol       Date:  2018-06-18       Impact factor: 4.849

Review 2.  Quality of life after carotid endarterectomy: a review of the literature.

Authors:  Mariusz Chabowski; Anna Grzebien; Agnieszka Ziomek; Karolina Dorobisz; Michał Leśniak; Dariusz Janczak
Journal:  Acta Neurol Belg       Date:  2017-06-21       Impact factor: 2.396

3.  Quality of life after stroke: impact of clinical and sociodemographic factors.

Authors:  Maria José Melo Ramos-Lima; Ismênia de Carvalho Brasileiro; Tamires Layane de Lima; Pedro Braga-Neto
Journal:  Clinics (Sao Paulo)       Date:  2018-10-08       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.